Gyre Therapeutics, Inc.
GYREHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeGyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company carries a $620.3M market cap, placing it firmly in the small-cap category. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Market Cap
$620.3M
Beta
4.74
P/E (TTM)
—
P/E (Fwd)
97.50
EPS (TTM)
$-0.25
EPS (Fwd)
$0.06
ROE
-17.4%
ROA
-5.4%
Cash
$74.8M
Total Debt
$3.4M
Free CF
$1.9M
52W Change
-27.1%
Annual Financials
Cash vs Debt
Where GYRE stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, GYRE finished 9.91% below its 150-day moving average ($6.76) and 13.62% below its 200-day moving average ($7.05). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GYRE overbought or oversold?
At the October 20, 2026 close, GYRE's RSI(14) was 25.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Gyre Therapeutics, Inc. holds $74.8M in cash against $3.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $1.9M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -17.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $102.3M to $116.6M.
A beta of 4.74 means GYRE is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing GYRE's risk profile alongside its fundamentals and technical indicators provides a more complete picture.